Advisory Services Network, LLC Uni Qure N.V. Transaction History

Advisory Services Network, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$4.82 - $6.93 $7,230 - $10,395	1,500 Added 12.0%	14,000 $72,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $83,875 - $147,875	12,500 New	12,500 $83,000
Q3 2021 Nov 05, 2021	SELL	$26.01 - $38.22 $68,926 - $101,283	-2,650 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$29.97 - $37.17 $79,420 - $98,500	2,650 New	2,650 $82,000
Q1 2021 May 24, 2021	SELL	$29.24 - $42.03 $30,702 - $44,131	-1,050 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$35.35 - $50.67 $37,117 - $53,203	1,050 New	1,050 $38,000
Q4 2019 Feb 04, 2020	SELL	$37.13 - $74.62 $2,413 - $4,850	-65 Closed	0 $0
Q1 2019 May 20, 2019	SELL	$27.39 - $68.41 $15,940 - $39,814	-582 Reduced 89.95%	65 $4,000
Q4 2018 Feb 15, 2019	SELL	$22.8 - $33.93 $87,483 - $130,189	-3,837 Reduced 85.57%	647 $19,000
Q2 2018 Jul 27, 2018	SELL	$21.96 - $39.94 $461 - $838	-21 Reduced 0.47%	4,484 $143,000
Q1 2018 Apr 23, 2018	BUY	$17.1 - $26.61 $55,233 - $85,950	3,230 Added 253.33%	4,505 $0
Q4 2017 Feb 08, 2018	BUY	$9.47 - $19.59 $12,074 - $24,977	1,275	1,275 $25,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.